1. Home
  2. SVRA vs ENOV Comparison

SVRA vs ENOV Comparison

Compare SVRA & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savara Inc.

SVRA

Savara Inc.

N/A

Current Price

$5.05

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Enovis Corporation

ENOV

Enovis Corporation

N/A

Current Price

$18.05

Market Cap

1.0B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
SVRA
ENOV
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2009
2008

Fundamental Metrics

Financial Performance
Metric
SVRA
ENOV
Price
$5.05
$18.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$10.94
★ $38.33
AVG Volume (30 Days)
1.5M
★ 1.8M
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$4.08
Revenue Next Year
$3,963.52
$4.89
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$3.34
$17.30
52 Week High
$7.01
$34.28

Technical Indicators

Market Signals
Indicator
SVRA
ENOV
Relative Strength Index (RSI) 45.29 36.54
Support Level $5.16 $17.30
Resistance Level $5.49 $26.97
Average True Range (ATR) 0.22 0.85
MACD -0.01 0.25
Stochastic Oscillator 45.11 32.64

Price Performance

Historical Comparison
SVRA
ENOV

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

About ENOV Enovis Corporation

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

Share on Social Networks: